Advances in immuno-oncology and precision oncology: Where are we heading?
Open Access
- 27 September 2021
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 6 (3), 109-110
- https://doi.org/10.25259/ijmio_19_2021
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaThe New England Journal of Medicine, 2021
- Immune checkpoint inhibitors in patients with solid tumors and poor performance statusMedicine, 2021
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerThe New England Journal of Medicine, 2021
- Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.Journal of Clinical Oncology, 2021
- Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2020
- KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsThe New England Journal of Medicine, 2020
- MA15.01 Immunogram for Cancer-Immunity Cycle towards Personalized Immunotherapy of Lung CancerJournal of Thoracic Oncology, 2017
- Advancements in Next-Generation SequencingAnnual Review of Genomics and Human Genetics, 2016